作者@article {RathoreS44 = {Geetanjali拉索尔教授},title ={类固醇Un-Responsive脑病与自身免疫性甲状腺炎(SUEAT)在儿科患者。},体积={99}={23补充2},页面= {S44——S44} = {2022}, doi = {wnl.0000903348.35087 10.1212/01.。出版商a1} = {Wolters Kluwer健康,公司代表美国神经病学学会},文摘={目的我们报告的一系列脑病患儿伴有甲状腺抗体耐火类固醇单药治疗。首页背景类固醇响应性脑病与自身免疫性甲状腺炎(SREAT)是一种罕见的疾病,只有几个孤立的儿童病例报道。用类固醇治疗后,临床明显改善是SREAT的一个标志。设计/方法IRB批准图审查是对病人进行\ < 18岁诊断出患有自身免疫性脑炎。回顾性分析临床特点,诊断测试,对治疗的反应和长期随访对患者阳性Thyroperoxidase (TPO)抗体。结果52例患者\ < 18岁被诊断出患有自身免疫性脑炎、10(19.2 \ %)这些都是传真照片抗体阳性。平均发病年龄为14.5岁(范围6 - 18年)只有1男性病人。精神状态(90 \ %)和行为变化(100 \ %)是最常见的演讲,发现只有1例癫痫发作。核磁共振(20 \ %)和脑电图(30 \ %)异常罕见,而且只有1病人脑脊液(CSF)的炎症的证据。自身免疫性脑炎和多种抗体面板-除了2(20 \ %)患者伴随的甲状腺球蛋白(TG)抗体。所有的病人需要额外的丙种球蛋白类固醇治疗后,7(70 \ %)患者接受利妥昔单抗和3(30 \ %)患者血浆置换联合需要。 All patients recovered at an average of 4.4 years follow up.Conclusions Encephalopathy associated with thyroid antibodies can be steroid unresponsive in the pediatric population. Further immune therapy, including plasmapheresis, should be considered in these patients, even in the absence of other para-clinical evidence of inflammation.}, issn = {0028-3878}, URL = {//www.ez-admanager.com/content/99/23_Supplement_2/S44.1}, eprint = {//www.ez-admanager.com/content/99/23_Supplement_2/S44.1.full.pdf}, journal = {Neurology} }